|Bid||1.0700 x 1100|
|Ask||1.1200 x 1000|
|Day's Range||1.0746 - 1.1390|
|52 Week Range||0.2200 - 10.8000|
|Beta (3Y Monthly)||2.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease. Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).